Vitro Biopharma, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Vitro BioPharma shows severe financial distress with stockholders' deficit of $16.1M, total liabilities exceeding assets by over 4x, and continued operating losses of $1.2M despite revenue growth. The company has massive debt obligations of $21M against only $493K cash, creating immediate liquidity concerns.
Red Flags Detected (7)
Stockholders' deficit of $16.1M indicating technical insolvency
Total liabilities of $21M vs total assets of $4.9M
Cash declined to $493K with current liabilities of $5.4M
4 more red flags detected
Key Takeaways
Company is technically insolvent with liabilities exceeding assets by $16.1M
Despite 18% revenue growth, operating losses continue at $1.2M quarterly
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.